MCC950 Sodium

Catalog No.S7809 Batch:S780908

Print

Technical Data

Formula

C20H23N2O5S.Na
Molecular Weight 426.46 CAS No. 256373-96-3
Solubility (25°C)* In vitro Water 43 mg/mL (100.83 mM)
Ethanol 43 mg/mL (100.83 mM)
DMSO Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
saline
43.0mg/ml Taking the 1 mL working solution as an example, add 43 mg of this product to 1 ml of physiological saline (0.9% NaCL solution), mix evenly to make it clear, The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description MCC950 Sodium is a potent, selective inhibitor of NLRP3 with IC50 of 7.5 nM in BMDMs; but not the AIM2, NLRC4 or NLRP1 inflammasomes.
Targets
NLRP3 [1]
(in BMDM (bone marrow derived macrophages))		 NLRP3 [1]
(in HMDM)
7.5nM 8.1 nM
In vitro

MCC950 inhibits canonical and noncanonical NLRP3 activation in BMDM and HMDM cells at IC50 of 7.5 and 8.1nM. MCC950 specifically inhibits activation of NLRP3 but not the AIM2, NLRC4 or NLRP1 inflammasomes.[1]
In vivo

MCC950 reduces interleukin-1β (IL-1β) production and attenuates the severity of experimental autoimmune encephalomyelitis (EAE). Furthermore, MCC950 treatment rescues neonatal lethality in a mouse model of CAPS and is active in ex vivo samples from individuals with Muckle-Wells syndrome. [1]

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    H9c2 cardiomyocyte cells

  • Concentrations

    7 nM

  • Incubation Time

    24 h

  • Method

    Cardiomyocytes were treated with NLRP3 inhibitor MCC950 for 24 h.
Animal Study:

[1]
  • Animal Models

    C57BL/6 mice

  • Dosages

    50 mg/kg

  • Administration

    i.p.

Customer Product Validation

Data from [Data independently produced by , , ARTHRITIS & RHEUMATOLOGY, 2017, 69(8):1636-1646]

Data from [Data independently produced by , , Biochem Pharmacol, 2018, 154:278-292]

Data from [Data independently produced by , , Biochem Biophys Res Commun, 2018, 503(4):3031-3037]

Data from [Data independently produced by , , BMC Complement Altern Med, 2018, 18(1):192]

Selleck's MCC950 Sodium has been cited by 158 publications

Experimental TET2 Clonal Hematopoiesis Predisposes to Renal Hypertension Through an Inflammasome-Mediated Mechanism [ Circ Res, 2024, 135(9):933-950] PubMed: 39234670
Osteopontin deficiency promotes cartilaginous endplate degeneration by enhancing the NF-κB signaling to recruit macrophages and activate the NLRP3 inflammasome [ Bone Res, 2024, 12(1):53] PubMed: 39242551
P2X7R Modulates NEK7-NLRP3 Interaction to Exacerbate Experimental Autoimmune Prostatitis via GSDMD-mediated Prostate Epithelial Cell Pyroptosis [ Int J Biol Sci, 2024, 20(9):3393-3411] PubMed: 38993566
YOD1 protects against MRSA sepsis-induced DIC through Lys33-linked deubiquitination of NLRP3 [ Cell Death Dis, 2024, 15(5):360] PubMed: 38789414
Tonic TCR and IL-1β signaling mediate phenotypic alterations of naive CD4+ T cells [ Cell Rep, 2024, 43(3):113954] PubMed: 38492221
A stress sensor, IRE1α, is required for bacterial-exotoxin-induced interleukin-1β production in tissue-resident macrophages [ Cell Rep, 2024, 43(4):113981] PubMed: 38520688
RVFV virulence factor NSs triggers the mitochondrial MCL-1-BAK axis to activate pathogenic NLRP3 pyroptosis [ PLoS Pathog, 2024, 20(8):e1012387] PubMed: 39213434
UCP2 knockout exacerbates sepsis-induced intestinal injury by promoting NLRP3-mediated pyroptosis [ Int Immunopharmacol, 2024, 141:112935] PubMed: 39159561
C4b-Binding Protein and Factor H Inhibit Inflammasome Activation during Group A Streptococci Infection in Human Cells [ J Innate Immun, 2024, 1-25.] PubMed: 39496236
sTREM2 Differentially Affects Cytokine Expression in Myeloid-Derived Cell Models via MAPK-JNK Signaling Pathway [ Biology (Basel), 2024, 13(2)87] PubMed: 38392305

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.